Introduction
You receive your pathology report after a TURBT.
Most patients expect to see words like:
- Ta
- T1
- Low-grade
- High-grade
Instead, you see:
Carcinoma In Situ (CIS)
Immediately, questions arise:
Is CIS cancer?
Is it invasive?
Do I need bladder removal?
Why is my doctor recommending BCG?
The answers can be confusing because CIS behaves differently from most bladder tumors.
Unlike the typical bladder tumor that grows outward into the bladder cavity, CIS is often:
- Flat
- Difficult to see
- High-grade
- Potentially aggressive
In fact, despite appearing superficial, CIS is considered one of the highest-risk forms of non-muscle invasive bladder cancer.
Understanding CIS is essential because early recognition and treatment can dramatically affect outcomes.
What Is Carcinoma In Situ?
Carcinoma in situ means:
Cancer cells are present in the bladder lining
but
They have not invaded deeper tissues
The cancer remains confined to:
The Urothelium
which is the inner lining of the bladder.
This places CIS within the category of:
Non-Muscle Invasive Bladder Cancer (NMIBC)
However:
CIS behaves very differently from many other NMIBC tumors.
Why Is CIS Different?
Most bladder tumors form visible growths.
They often look like:
- Papillary tumors
- Finger-like projections
- Small cauliflower-like lesions
CIS does not.
Instead:
The cancer spreads along the bladder lining.
This creates:
Flat Cancer
which may appear as:
- Red patches
- Velvety mucosa
- Inflamed tissue
Sometimes it is nearly invisible.
Is CIS Cancer?
Absolutely.
This is a common misunderstanding.
Some patients hear:
“It’s only on the surface.”
and assume it is not serious.
In reality:
CIS is:
High-Grade Cancer
by definition.
There is no such thing as:
Low-Grade CIS
Every CIS lesion is considered high-grade.
Why Is CIS Considered High Risk?
Because it has a substantial risk of:
Recurrence
and
Progression
If untreated:
CIS may eventually invade:
- Lamina propria
- Bladder muscle
Once muscle invasion occurs, treatment becomes much more complex.
How Common Is CIS?
CIS may occur:
Alone
called:
Primary CIS
or
Together With Other Tumors
such as:
- Ta tumors
- T1 tumors
The combination of T1 disease and CIS often indicates particularly high-risk biology.
What Causes CIS?
The risk factors are largely similar to those for bladder cancer overall.
The strongest include:
Smoking
Occupational Chemical Exposure
Increasing Age
Male Sex
Chronic Urothelial Injury
Smoking remains the single most important preventable risk factor.
What Symptoms Does CIS Cause?
Many patients develop:
Irritative Urinary Symptoms
including:
- Frequency
- Urgency
- Burning urination
This differs from many papillary tumors, which often cause only bleeding.
Can CIS Cause Blood in the Urine?
Yes.
Patients may experience:
Visible Blood
or
Microscopic Hematuria
However:
Some patients have no bleeding at all.
Why Is CIS Difficult to Diagnose?
One of the challenges is that CIS may be:
Hard to See
during routine cystoscopy.
The lesions can be subtle.
Sometimes they resemble:
- Inflammation
- Infection
- Benign irritation
This is why additional diagnostic tools are sometimes necessary.
How Is CIS Diagnosed?
Diagnosis usually involves several components.
Cystoscopy
The first step.
The bladder is inspected directly.
Suspicious areas are biopsied.
Bladder Biopsy
This is required for definitive diagnosis.
Pathology confirms the presence of CIS.
Urine Cytology
CIS frequently sheds abnormal cells into the urine.
As a result:
Urine cytology is often positive.
In fact:
A positive urine cytology with no obvious tumor sometimes raises suspicion for occult CIS.
Enhanced Cystoscopy
Advanced techniques may improve detection.
Examples include:
Blue Light Cystoscopy
and
Narrow Band Imaging (NBI)
These technologies can reveal lesions that might otherwise be missed.
What Does the Pathology Report Look Like?
A typical report may state:
Urothelial Carcinoma In Situ
High Grade
No Evidence of Invasion
The key finding is:
Absence of Invasion
Once invasion occurs, the stage changes.
What Is the Standard Treatment?
For most patients:
BCG Immunotherapy
is the gold standard.
Why BCG?
BCG activates the immune system inside the bladder.
It is particularly effective against:
CIS
In fact:
CIS is one of the strongest indications for BCG therapy.
What Does BCG Treatment Involve?
Most patients receive:
Induction BCG
Once weekly
for
Six Weeks
Afterward:
Maintenance BCG is often recommended.
How Effective Is BCG for CIS?
Many patients achieve:
Complete Response
meaning no detectable CIS remains.
Response rates are generally excellent.
However:
Long-term surveillance remains necessary.
What If BCG Doesn’t Work?
This situation is called:
BCG-Unresponsive Disease
The risk of progression becomes higher.
Treatment options may include:
Radical Cystectomy
Gene Therapy
Novel Intravesical Therapies
Clinical Trials
Do All Patients Need Bladder Removal?
No.
Most patients start with bladder-preserving treatment.
However:
Some patients eventually require:
Radical Cystectomy
particularly if:
- BCG fails
- CIS persists
- Progression occurs
What Is the Prognosis?
The outlook depends heavily on:
- Response to BCG
- Presence of other tumors
- Progression risk
When treated appropriately:
Many patients achieve long-term disease control.
Why Is Surveillance So Important?
Even after successful treatment:
CIS can recur.
Patients typically require:
Cystoscopy
Urine Cytology
Long-Term Follow-Up
for many years.
Frequently Asked Questions
Is CIS invasive cancer?
No.
By definition, CIS remains confined to the bladder lining.
Is CIS high-grade?
Yes.
All CIS is considered high-grade.
Can CIS be cured?
Many patients achieve complete responses with BCG.
Is CIS worse than Ta disease?
Generally yes.
CIS is considered a high-risk lesion.
Can CIS progress to muscle-invasive cancer?
Yes.
This is why prompt treatment is important.
Does CIS always require BCG?
BCG is the standard treatment for most eligible patients.
A Urologic Oncologist’s Perspective
Among all forms of NMIBC, CIS deserves particular respect.
It may look deceptively subtle.
It may produce minimal symptoms.
It may even be difficult to see.
Yet biologically, it is often more aggressive than many visible bladder tumors.
The encouraging news is that CIS is also one of the diseases for which BCG can be remarkably effective.
Early diagnosis and appropriate treatment are critical.
Final Verdict
Carcinoma in situ (CIS) is a high-grade, flat form of bladder cancer that remains confined to the bladder lining.
Although it is classified as non-muscle invasive disease, it carries a significant risk of recurrence and progression if untreated.
The most important message is this:
CIS is highly treatable, but it should never be underestimated.
Prompt diagnosis, appropriate BCG therapy, and long-term surveillance are essential for achieving the best possible outcomes.
